These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32501980)

  • 21. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
    Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.
    Konstas AG; Katsimbris JM; Lallos N; Boukaras GP; Jenkins JN; Stewart WC
    Ophthalmology; 2005 Feb; 112(2):262-6. PubMed ID: 15691561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews.
    Daka Q; Trkulja V
    Croat Med J; 2014 Oct; 55(5):468-80. PubMed ID: 25358880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
    Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
    BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting.
    Kook MS; Simonyi S; Sohn YH; Kim CY; Park KH
    Jpn J Ophthalmol; 2015 Sep; 59(5):325-34. PubMed ID: 26202440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study.
    Rubião F; Araújo ACF; Sancio JB; Nogueira BS; Franca JR; Nogueira JC; Ferreira AJ; Faraco AAG; Foureaux G; Cronemberger S
    Curr Drug Deliv; 2021; 18(7):1022-1026. PubMed ID: 33388018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma.
    Dirks MS; Noecker RJ; Earl M; Roh S; Silverstein SM; Williams RD
    Adv Ther; 2006; 23(3):385-94. PubMed ID: 16912020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
    Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM;
    Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
    Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
    Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.
    Harasymowycz P; Royer C; Cui AX; Barbeau M; Jobin-Gervais K; Mathurin K; Lachaine J; Beauchemin C
    Br J Ophthalmol; 2022 May; 106(5):640-647. PubMed ID: 33397657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
    Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M
    PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of Bushen Huoxue method in treating glaucoma: A protocol for systematic review and meta-analysis.
    Wang L; Yu T; Sun H; Liu R; Liu Y
    Medicine (Baltimore); 2020 Jul; 99(27):e21156. PubMed ID: 32629752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
    Ozturk F; Ermis SS; Inan UU
    Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension.
    Orme M; Collins S; Dakin H; Kelly S; Loftus J
    Curr Med Res Opin; 2010 Mar; 26(3):511-28. PubMed ID: 20014995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA; Cimino L
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial.
    Lewis RA; Christie WC; Day DG; Craven ER; Walters T; Bejanian M; Lee SS; Goodkin ML; Zhang J; Whitcup SM; Robinson MR;
    Am J Ophthalmol; 2017 Mar; 175():137-147. PubMed ID: 28012819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.
    DuBiner H; Cooke D; Dirks M; Stewart WC; VanDenburgh AM; Felix C
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S353-60. PubMed ID: 11434938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.